The DNBSEQ-T7 ultra-high-throughput sequencer, metagenomic sequencing kit for coronaviruses, and 2019-nCoV RT-qPCR kit have received authorization from China's NMPA.
The University of Utah spinout said it will use the funding to enhance and expand its NGS-based Explify microbe identification platform and support its lab.
Natera discussed its cancer and transplant rejection testing businesses, while Exact Sciences explained how it will benefit from its Genomic Health acquisition.
The funding supports development of a low-cost platform for detection of antimicrobial resistance elements in complex microbial communities.
MinIon sequencing identified pathogens and antimicrobial resistance genes in the gut of preterm infants with suspected necrotizing enterocolitis.
The French metagenomic sequencing firm received funding from both historical and new investors, including debt financing from Norgine Ventures.
The team is now conducting additional studies of mNGS in plasma, as well as looking to reduce turnaround time by running the test on a nanopore sequencer.
The company plans to take a tiered approach to assay development, targeting its first test to 10 viruses commonly detected in transplant patients.
The method, presented at the European Congress of Clinical Microbiology and Infectious Diseases, may provide results in hours rather than a week or more.
While the study showed initial promise, further work will be necessary to clarify its performance for various clinical indications.